Background: Until now, multiple reviews on the pharmacological treatment of dementia have been published. Methods: We performed a scoping review to summarize research findings and to identify gaps in the existing literature. We searched the literature and assessed the risk of bias of the included reviews. A team of clinical experts assessed the fields in which more research is necessary. Fifty-five reviews with a low risk of bias were included, most of them concerning the treatment of cognitive decline (n = 16) and behavioral symptoms (n = 10) in Alzheimer's disease (AD). For cognitive impairment, cholinesterase inhibitors (n = 13) and memantine (n = 7) were described most frequently. Little information was found about the treatment of depression in dementia. Conclusions: For many current treatments, there is sufficient evidence. New research should focus on the symptomatic treatment of the earliest and most salient complaints in AD as well as on disease-modifying interventions acting at the level of the amyloid cascade. (c) 2013 S. Karger AG, Basel.
        
Related information
Citations formats
van de Glind EM, van Enst WA, van Munster BC, Olde Rikkert MG, Scheltens P, Scholten RJ, Hooft L (2013) Pharmacological Treatment of Dementia: A Scoping Review of Systematic Reviews Dementia & Geriatric Cognitive Disorders36: 211-228
van de Glind EM, van Enst WA, van Munster BC, Olde Rikkert MG, Scheltens P, Scholten RJ, Hooft L (2013) Dementia & Geriatric Cognitive Disorders36: 211-228